|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
gptkb:C10AA05
|
|
gptkbp:bioavailability
|
14%
|
|
gptkbp:brand
|
gptkb:Lipitor
Sortis
Torvast
Atoris
Atorvastatin Calcium
Tahor
Totalip
|
|
gptkbp:CASNumber
|
134523-00-5
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
active liver disease
|
|
gptkbp:eliminationHalfLife
|
14 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasInChIKey
|
XUKUURHRXDUEBC-KAYWLYCHSA-N
|
|
gptkbp:hasMolecularFormula
|
C33H35FN2O5
|
|
gptkbp:hasPatentExpiry
|
2011 (US)
|
|
gptkbp:hasSMILES
|
CC(C)C1=CC=C(C=C1)C2C(C(=O)O)N(C(=O)C3=CC=CC=C3F)C(=O)C4=CC=CC=C4C2=O
|
|
gptkbp:hasUNII
|
O95139Z8L1
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB01008
|
|
gptkbp:indication
|
gptkb:familial_hypercholesterolemia
dyslipidemia
prevention of cardiovascular disease
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
HMG-CoA reductase inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
558.64
|
|
gptkbp:name
|
gptkb:Atorvastatin
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
gptkb:D07481
gptkb:DB01008
60823
CHEBI:15355
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
liver enzyme abnormalities
muscular dystrophy
rhabdomyolysis
|
|
gptkbp:synonym
|
atorvastatin calcium
atorvastatin calcium trihydrate
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
|
|
gptkbp:target
|
gptkb:HMGCR
|
|
gptkbp:bfsParent
|
gptkb:busulfan
|
|
gptkbp:bfsLayer
|
7
|